Health
Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers – CGTN
If the study is successful, the companies could submit the vaccine for regulatory approval as early as October, putting them on track to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021.
Pfizer and BioNTech on Saturday proposed to the U.S. Food and Drug Administration (FDA) to expand their phase three pivotal COVID-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
The initial target figure for the trial was up to 30,000 participants, which the companies said in a joint statement that they expect to reach by next week.
The proposed expansion would also allow the companies to enroll people as young as 16 and people with chron…
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General13 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News21 hours agoStudents say new facility would be better in rural areas of Queensland
-
Noosa News10 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland